Clinical Trials

Find a Trial

Trial Summary

Protocol No.PHO-COG-CROOP-ADVL1312
Principal InvestigatorCroop, James
PhasePhase I/II
Age GroupChildren
TitleADVL1312, A Phase 1/2 Study of MK-1775 (AZD1775, IND# 121422) in Combination with Oral Irinotecan in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Tumors
DescriptionThis phase I/II trial studies the side effects and best dose of WEE1 inhibitor MK-1775 and irinotecan hydrochloride in treating younger patients with solid tumors that have come back or that have not responded to standard therapy. WEE1 inhibitor MK-1775 and irinotecan hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Key EligibilityIn order to be eligible to take part in this trial, patients must meet the following criteria:

  • Patients must have had histologic verification of malignancy at original diagnosis or relapse except in patients with intrinsic brain stem tumors, optic pathway gliomas, or patients with pineal tumors and elevations of cerebrospinal fluid (CSF) or serum tumor markers including alpha-fetoprotein or beta-human chorionic gonadotropin (HCG)
  • Patient's current disease state must be one for which there is no known curative therapy or therapy proven to prolong survival with an acceptable quality of life
For a full list of participation criteria, please visit
Applicable Disease SitesChildhood Cancers
Participating InstitutionsIndiana University (IU)
  • Riley Hospital for Children
Treatment TypeTreatment
ContactMelissa Lee, Phone: +1 317-944-4281
Pager: 312-1228